Physician profile
Lawrence E Ginsberg
NPI 1336247907
$8,576.72
in general payments reported to CMS, 2019-2025
11 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,142 · 2022: $2,686 · 2023: $277 · 2024: $222 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,121.13 | 2019 | |
| Abbvie INC. | $2,500.00 | 2022 | |
| Tris Pharma INC | $543.02 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Janssen Pharmaceuticals, INC | $120.53 | 2022 | |
| Idorsia Pharmaceuticals US INC | $92.42 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $90.65 | 2024-2025 | Xelstrym, Secuado |
| Lundbeck LLC | $52.44 | 2023-2024 | Rexulti |
| Arbor Pharmaceuticals, INC. | $20.77 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.29 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $16.47 | 2023 | Trintellix |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Ginsberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.